BACHEM HOLDING AG banner

Intrinsic Value

BHM price has not been updated for more than 3 years. This may indicate that the stock has been delisted.

The intrinsic value of BACHEM HOLDING AG (BHM) under the Base Case is 7.72 EUR per share. Compared with the current market price of 10.2 EUR, the stock appears Overvalued by 24% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

BHM Intrinsic Value
€7.72
Overvaluation 24%
Intrinsic Value
Price €10.2
Alert me when BHM is below its intrinsic value
Today €6.18 · 39.4% below the current price

We don’t have enough historical valuation data to make this comparison.

Alternatives to BHM

Fundamental Analysis

What BACHEM Does

Life Sciences Tools & Services Health Care

Bachem Holding AG makes custom peptide and oligonucleotide ingredients for the pharmaceutical industry. In plain English, it helps drug makers design and produce hard-to-make molecules that often become the active part of medicines, especially in areas like diabetes, cancer, and rare diseases. Its customers are mainly big drug companies and biotech firms that need a specialist partner to develop and manufacture these compounds under strict quality rules.

Headquarters
Switzerland CH
Employees
2 511
IPO date
Jun 29, 2001
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue BHM Research

Decided on BACHEM HOLDING? Get an email when BHM reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one BHM stock?

The intrinsic value for BACHEM HOLDING AG (BHM) under the Base Case is 7.72 EUR.

Is BHM stock undervalued or overvalued?

Compared with the current market price of 10.2 EUR, the stock appears Overvalued by 24% .

How reliable are our estimates? See how past valuations played out
Back to Top